Navigation Links
Docetaxel May Boost Outcomes For Breast Cancers That Haven't Spread to Lymph
Date:12/1/2010

By Kathleen Doheny
HealthDay Reporter

WEDNESDAY, Dec. 1 (HealthDay News) -- A chemotherapy regimen already proven superior to other regimens for breast cancer that has spread to the lymph nodes may also work better for some women whose cancers haven't spread, a new study has found.

When it came to these "node-negative" cancers, the drug combination of docetaxel, doxorubicin and cyclophosphamide (dubbed TAC) outperformed the combination of fluorouracil, doxorubicin, and cyclophosphamide (FAC), the Spanish study authors said.

The TAC regimen was better at keeping women alive and disease-free after a median follow up of almost six and a half years, the study found.

''For those women with higher-risk, node-negative breast cancer, in which chemotherapy is indicated, TAC is one of the most interesting options," said study co-author Dr. Miguel Martin, a professor of medical oncology at the Hospital General Universitario Gregorio Maranon in Madrid.

The study was funded by the drug maker Sanofi-Aventis -- which makes Taxotere, the brand name for docetaxel -- and GEICAM, the Spanish Breast Cancer Research Group. The results are published in the Dec. 2 issue of the New England Journal of Medicine.

To determine which women with breast cancer would benefit from adjuvant chemotherapy (typically chemotherapy after surgery), doctors take into account a number of risk factors, such as the patient's age, tumor size and other characteristics.

For the new study, the researchers assigned 1,060 women with breast cancers that were axillary-node negative who had at least one high-risk factor for recurrence to one of the two treatment regimens every three weeks for six cycles after their surgery.

At the 77-month mark, almost 88 percent of the TAC women were alive and disease-free, compared to close to 82 percent of the women in the FAC group. Those in the TAC group had a 32 percent reduction in the risk of recurrence, the study authors said.

The reduced risk held true even after taking into account a number of high-risk factors, such as age, the women's menopausal status and tumor characteristics.

The differences in survival rates weren't significant from a statistical point of view -- 95.2 percent of TAC-treated women survived the follow-up, compared to 93.5 percent of the FAC-treated women.

However, adverse events from the drugs were more common with TAC -- 28 percent of patients, compared to 17 percent of the FAC patients.

''TAC is more toxic," Martin said, adding that ''all the toxicities were reversible." One common side effect was neutropenia, an abnormally low number of white blood cells. Fatigue was also a problem, the study found.

Another consideration: TAC chemotherapy is also substantially more expensive than FAC, Martin said, although he could not specify exactly how much more.

Even so, he said, "I think this study provides grounds for thinking of this regimen, particularly for those women with high-risk node-negative breast cancers."

Dr. Minetta Liu, director of translational breast cancer research at the Lombardi Comprehensive Cancer Center at Georgetown University, said the new study supports what many oncologists are already doing.

"Many oncologists are incorporating taxenes [such as docetaxel] in the adjuvant treatment for node-negative breast cancer," said Liu, who reviewed the study findings but was not involved with the research.

The ongoing challenge, Liu said, is deciding which women need the additional therapy. "This particular study's importance is that it illustrates there is a benefit in incorporating a taxene into the adjuvant treatment for some women with node-negative breast cancer."

More information

To learn more about breast cancer treatment, visit the U.S. National Cancer Institute.

SOURCES: Miguel Martin, M.D., Ph.D., professor of medical oncology, Hospital General Universitario Gregorio Maranon, Madrid, Spain; Minetta Liu, M.D., director of translational research, Georgetown Lombardi Comprehensive Cancer Center, Washington, D.C.; New England Journal of Medicine, Dec. 2, 2010


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Vandetanib shows clinical benefit when combined with docetaxel for lung cancer
2. New lung disease network to benefit patients and boost UK economy
3. Love Hormone May Boost Mens Memories of Mom -- Good or Bad
4. Love Hormone Boosts Memories of Mom -- Good or Bad, Study Finds
5. Behavior Disorders Boost Crash Risk for Teen Boys: Study
6. Poor Children Get Biggest Literacy Boost From Preschool
7. Higher Plavix Dose Wont Boost Outcomes After Stent Placement: Study
8. Scientists Find Way to Boost Good Cholesterol in Mice
9. Setting National Hospital Standards Could Boost Cardiac Care
10. Small assist device used in emergency case as twin, heart booster pumps for first time in US
11. Math Skills Boost Couples Financial Worth: Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... April 28, 2017 , ... ... the integration of Microsoft(R) Word(TM) Online(TM), which enables sleep physicians to create and ... streamlines the reporting process and provides a familiar interface that does not require ...
(Date:4/28/2017)... Pass, OR (PRWEB) , ... April 28, 2017 ... ... Ijose, http://www.foodsthathealdaily.com , http://www.wiredlifesolutions.com , “Computers are everywhere and they’re ... Hour Power of Water, Global Climate Change and Your Health on Voice America ...
(Date:4/28/2017)... ... April 28, 2017 , ... The Texas Cord Blood ... to the labor and delivery team at Women’s Hospital at Renaissance in Edinburg for ... birth at the hospital and decide to donate. , “Women’s Hospital at Renaissance ...
(Date:4/28/2017)... ... , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh in Abilene, Texas, has ... which He does not. Yisrayl says with so many titles and names for the ... he says with a little Scripture, backed with a lot of research, the truth is ...
(Date:4/28/2017)... ... , ... NuevaCare, a leading home care agency based in San Mateo, California, ... proud to announce information upgrades to its blog in the form of WordPress tags. ... such as home care (generally) as well as senior care and home care agency ...
Breaking Medicine News(10 mins):
(Date:4/19/2017)... , April 19, 2017  Novartis today ... the National Heart, Lung, and Blood Institute (NHLBI) ... that 58% of patients with treatment-naïve severe aplastic ... when treated with eltrombopag at the initiation of ... The study evaluated three sequential treatment groups, or ...
(Date:4/18/2017)... DUBLIN, Ohio , April 18, 2017  Cardinal ... its Non-GAAP 1 fiscal 2017 earnings per share ... 2018 and 2019.  This is in conjunction with this ... Care, Deep Vein Thrombosis and Nutritional Insufficiency businesses. ... EPS from continuing operations will be at the bottom ...
(Date:4/18/2017)... Viverae ® , a leader in workplace ... IBM ® Watson Campaign Automation, implementing behavioral messaging ... a personalized experience. Through digital engagement, the platform prompts ... real time. The enhanced experience drives engagement by focusing ... they are in their journey to health. ...
Breaking Medicine Technology: